JPS6236482B2 - - Google Patents
Info
- Publication number
- JPS6236482B2 JPS6236482B2 JP10597879A JP10597879A JPS6236482B2 JP S6236482 B2 JPS6236482 B2 JP S6236482B2 JP 10597879 A JP10597879 A JP 10597879A JP 10597879 A JP10597879 A JP 10597879A JP S6236482 B2 JPS6236482 B2 JP S6236482B2
- Authority
- JP
- Japan
- Prior art keywords
- nicotinic acid
- compound
- following
- alkyl
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 150000001875 compounds Chemical class 0.000 claims description 9
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000003472 antidiabetic agent Substances 0.000 claims description 2
- 125000006165 cyclic alkyl group Chemical group 0.000 claims description 2
- 229940126904 hypoglycaemic agent Drugs 0.000 claims description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 6
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 230000002218 hypoglycaemic effect Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 235000005152 nicotinamide Nutrition 0.000 description 4
- 239000011570 nicotinamide Substances 0.000 description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229960003512 nicotinic acid Drugs 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 2
- 150000003973 alkyl amines Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
- 229960001052 streptozocin Drugs 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000027219 Deficiency disease Diseases 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 206010029400 Nicotinic acid deficiency Diseases 0.000 description 1
- 208000002141 Pellagra Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- MSYBLBLAMDYKKZ-UHFFFAOYSA-N hydron;pyridine-3-carbonyl chloride;chloride Chemical compound Cl.ClC(=O)C1=CC=CN=C1 MSYBLBLAMDYKKZ-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- ZXOAHASJYIUCBG-UHFFFAOYSA-N n-ethylpyridine-3-carboxamide Chemical compound CCNC(=O)C1=CC=CN=C1 ZXOAHASJYIUCBG-UHFFFAOYSA-N 0.000 description 1
- ULLMVAPKQOJUCZ-UHFFFAOYSA-N n-propan-2-ylpyridine-3-carboxamide Chemical compound CC(C)NC(=O)C1=CC=CN=C1 ULLMVAPKQOJUCZ-UHFFFAOYSA-N 0.000 description 1
- YIEIQMFWAGTFCB-UHFFFAOYSA-N n-propylpyridine-3-carboxamide Chemical compound CCCNC(=O)C1=CC=CN=C1 YIEIQMFWAGTFCB-UHFFFAOYSA-N 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- -1 nicotinic acid halide Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
Landscapes
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP10597879A JPS5630919A (en) | 1979-08-22 | 1979-08-22 | Hypoglycemic agent |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP10597879A JPS5630919A (en) | 1979-08-22 | 1979-08-22 | Hypoglycemic agent |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS5630919A JPS5630919A (en) | 1981-03-28 |
JPS6236482B2 true JPS6236482B2 (fr) | 1987-08-07 |
Family
ID=14421836
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP10597879A Granted JPS5630919A (en) | 1979-08-22 | 1979-08-22 | Hypoglycemic agent |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS5630919A (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115974778A (zh) * | 2021-10-14 | 2023-04-18 | 南京华狮新材料有限公司 | 一种高效透皮吸收的烟酰胺衍生物及其制备方法 |
-
1979
- 1979-08-22 JP JP10597879A patent/JPS5630919A/ja active Granted
Also Published As
Publication number | Publication date |
---|---|
JPS5630919A (en) | 1981-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPS6023102B2 (ja) | 新規エピニンエステル、その製法及び医薬組成物 | |
KR950004677B1 (ko) | 히드록시알킬시스테인 유도체 및 이를 함유하는 거담제 | |
JPS6229566A (ja) | 新規グアニジノメチル安息香酸誘導体 | |
US20050130930A1 (en) | Adenosine derivatives and use thereof | |
JPH059424B2 (fr) | ||
CS204008B2 (en) | Process for preparing new derivatives of 0-/3-amino-2-hydroxypropyl/-amidoxime | |
US3519717A (en) | Novel method for lowering high blood pressure and compositions therefor | |
KR860001578B1 (ko) | 3-티오메틸 파리딘 유도체의 제조방법 | |
US5747521A (en) | N-cinnamoyl-2-methyl-5-methoxy-3-indoleacetic acid ester, and pharmaceutical preparation containing the same | |
US4029803A (en) | Method of treatment with 2-iminothiazolidines and thiazolines | |
JPS6159288B2 (fr) | ||
JPS6236482B2 (fr) | ||
EP0105458B1 (fr) | Dérivés d'acide alpha-aryl-alpha-pyridylalkanoique, procédé pour leur préparation et composition pharmaceutique les contenant | |
JPH0365338B2 (fr) | ||
KR880002002B1 (ko) | N-(1,3-디티올란-2-일리덴)아닐린 유도체 및 이의 제조방법 | |
US20120270908A1 (en) | Substituted 3 -hydrozypyridines and pharmaceutical compositions thereof | |
KR880001865B1 (ko) | 4-(1-이미다졸일메틸)신남산 하이드로클로라이드 모노하이드레이트의 제조방법 | |
JPS6124374B2 (fr) | ||
JPS61158980A (ja) | 8α‐アシルアミノエルゴリン類、その製法および医薬組成物 | |
US4338319A (en) | Method for the treatment of chronic obstructive airway or cardiac diseases | |
US3005818A (en) | 1-phenyl-2, 3-dimethyl-4-morpholino methyl pyrazolone-(5) compounds | |
JPS5835186A (ja) | ジカルボキシアミノチアゾール誘導体およびそれを含有する免疫調節組成物 | |
US3907999A (en) | Substituted dibenzocyclooctene compositions | |
US20080242657A1 (en) | Treatment of Tremor with Histamine H3 Inverse Agonists or Hist Amine H3 Antagonists | |
US4539317A (en) | 4-Substituted amino-3-[3-alkylindoloamino-2-hydroxypropoxy] thiadiazoles, compositions and pharmaceutical use |